Latest News
Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
- Corbus Pharmaceuticals develops CRB-913 to target obesity by blocking peripheral CB1 receptors
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
- Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
- Corbus Pharmaceuticals (CRBP) Slides 9.3% to $4.78, Nearing Key Support at $4.54 - Wave Equality
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
- Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38
- Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
- Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
Headlines from the last 30 days, linking to the original publishers. See all market news →